• 
  Sue Cheeseman, Bethany Levick, Will Sopwith, Hayley Fenton, Eun Ji Nam, et al.. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. Frontiers in Oncology, 2023, 13, pp.1114435. ⟨10.3389/fonc.2023.1114435⟩. ⟨hal-04756405⟩
• 
  Loic Ah-Thiane, Caroline Rousseau, Maud Aumont, Axel Cailleteau, Mélanie Doré, et al.. The Sentinel Lymph Node in Treatment Planning: A Narrative Review of Lymph-Flow-Guided Radiotherapy. Cancers, 2023, 15 (10), pp.2736. ⟨10.3390/cancers15102736⟩. ⟨hal-04755878⟩
• 
  Stéphane J.C. Mancini, Karl Balabanian, Isabelle Corre, Julie Gavard, Gwendal Lazennec, et al.. Deciphering Tumor Niches: Lessons From Solid and Hematological Malignancies. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.766275⟩. ⟨hal-04673450⟩
• 
  Gunjan Kayal, Nathaly Barbosa, Carlos Calderón Marín, Ludovic Ferrer, José-Alejandro Fragoso-Negrín, et al.. Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study. Journal of Nuclear Medicine, 2024, 65 (1), pp.125-131. ⟨10.2967/jnumed.122.265340⟩. ⟨hal-04753484⟩
• 
  Marcela Carausu, Matthieu Carton, Luc Cabel, Anne Patsouris, Christelle Levy, et al.. Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database. Therapeutic Advances in Medical Oncology, 2022, 14, pp.175883592210770. ⟨10.1177/17588359221077082⟩. ⟨hal-03867853⟩
• 
  Fabienne Lesueur, Noura Mebirouk, Yue Jiao, Laure Barjhoux, Muriel Belotti, et al.. GEMO, a National Resource to Study Genetic Modifiers of Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Pathogenic Variant Carriers. Frontiers in Oncology, 2018, 8, pp.490. ⟨10.3389/fonc.2018.00490⟩. ⟨hal-01926758⟩
• 
  Timothy Rebbeck, Tara Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, et al.. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. Human Mutation, 2018, 39 (5), pp.593-620. ⟨10.1002/humu.23406⟩. ⟨hal-02351570⟩
• 
  Marie Paule Sablin, Pierre Gestraud, Sarah Flora Jonas, Constance Lamy, Magali Lacroix-Triki, et al.. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. British Journal of Cancer, In press, ⟨10.1038/s41416-024-02804-6⟩. ⟨hal-04683939⟩
• 
  Jean Michel Lecerf, Carine Delayre, Océane Moulenq, Gregory Ninot, Bruno Raynard, et al.. Le plaisir alimentaire chez le patient traité pour un cancer Auteurs. Nutritions et Endocrinologie, 2024, Hors série, pp.25-28. ⟨hal-04684545⟩
• 
  Patricia Pautier, Antoine Italiano, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, et al.. Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.. Lancet Oncology, 2022, Lancet Oncology, 23 (8), pp.1044-1054. ⟨10.1016/S1470-2045(22)00380-1⟩. ⟨hal-04387055⟩
• 
  Julien Guérin, Amine Nahid, Louis Tassy, Marc Deloger, François Bocquet, et al.. Consore: A Powerful Federated Data Mining Tool Driving a French Research Network to Accelerate Cancer Research. International Journal of Environmental Research and Public Health, 2024, 21 (2), pp.189. ⟨10.3390/ijerph21020189⟩. ⟨inserm-04659888⟩
• 
  J.Y. Blay, N. Penel, T. Valentin, P. Anract, F. Duffaud, et al.. Improved nationwide survival of sarcoma patients with a network of reference centers. Annals of Oncology, 2024, 35 (4), pp.351-363. ⟨10.1016/j.annonc.2024.01.001⟩. ⟨inserm-04658953⟩
• 
  A. Le Cesne, J. Y. Blay, D. Cupissol, A. Italiano, C. Delcambre, et al.. A randomized phase III trial comparing trabectedin to best supportive care in patients with pre-treated soft tissue sarcoma: T-SAR, a French Sarcoma Group trial. Annals of Oncology, 2021, Annals of Oncology, 32 (8), p. 1034-1044. ⟨10.1016/j.annonc.2021.04.014⟩. ⟨hal-04522981⟩
• 
  Coline Montégut, Jean-Sébastien Guillamo, François Ducray, Caroline Dehais, Cohen-Jonathan Moyal Elisabeth, et al.. Predictive geriatric factors in elderly patients treated for idh-mutant high-grade gliomas: a French Pola network study. Neuro-Oncology, 2021, 23 (6), pp.153. ⟨10.1093/neuonc/noab196.600⟩. ⟨hal-03600574⟩
• 
  Jeremie Naffrichoux, Pierre Poupin, William Pouillot, Claude Linassier, Nathalie Rioux-Leclercq, et al.. PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩. ⟨hal-04615732⟩
• 
  Emeline Tabouret, François Bertucci, Jean-Yves Pierga, Thierry Petit, Christelle Levy, et al.. MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study. Oncotarget, 2016, 7 (14), pp.18531-18540. ⟨10.18632/oncotarget.7612⟩. ⟨hal-03623733⟩
• 
  Anne Patsouris, Kadija Diop, Olivier Tredan, Daniel Nenciu, Anthony Gonçalves, et al.. Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation. European Journal of Cancer, 2021, 159, pp.283-295. ⟨10.1016/j.ejca.2021.09.028⟩. ⟨hal-04522229⟩
• 
  Marie Lange, Sophie Lefevre Arbogast, Isabelle Hardy-Léger, Olivier Rigal, Johan Le Fel, et al.. Cognitive change in breast cancer patients up to 2 years after diagnosis. JNCI: Journal of the National Cancer Institute, 2022, 115 (3), pp.322-331. ⟨10.1093/jnci/djac240⟩. ⟨hal-03992251⟩
• 
  S. Peters, A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, et al.. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology, 2022, 33 (5), pp.488-499. ⟨10.1016/j.annonc.2022.01.074⟩. ⟨hal-04085315⟩
• 
  Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, et al.. Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort. Gynecologic Oncology, 2022, 167 (1), pp.11-21. ⟨10.1016/j.ygyno.2022.08.005⟩. ⟨hal-03868125⟩

265

299